Literature DB >> 28994419

Targeted therapy: ARIEL3 - broad benefit of PARP inhibitors in ovarian cancer.

David Killock.   

Abstract

Entities:  

Year:  2017        PMID: 28994419     DOI: 10.1038/nrclinonc.2017.161

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Robert L Coleman; Amit M Oza; Domenica Lorusso; Carol Aghajanian; Ana Oaknin; Andrew Dean; Nicoletta Colombo; Johanne I Weberpals; Andrew Clamp; Giovanni Scambia; Alexandra Leary; Robert W Holloway; Margarita Amenedo Gancedo; Peter C Fong; Jeffrey C Goh; David M O'Malley; Deborah K Armstrong; Jesus Garcia-Donas; Elizabeth M Swisher; Anne Floquet; Gottfried E Konecny; Iain A McNeish; Clare L Scott; Terri Cameron; Lara Maloney; Jeff Isaacson; Sandra Goble; Caroline Grace; Thomas C Harding; Mitch Raponi; James Sun; Kevin K Lin; Heidi Giordano; Jonathan A Ledermann
Journal:  Lancet       Date:  2017-09-12       Impact factor: 79.321

  1 in total
  2 in total

1.  Predictive immune biomarkers: an unattainable chimera?

Authors:  Anna Maria Trotta; Roberto Pacelli; Stefania Scala
Journal:  Cell Mol Immunol       Date:  2018-02-05       Impact factor: 11.530

2.  Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib ameliorates influenza-virus-induced pneumonia in mice.

Authors:  Wei Liu; Xiaojuan Ren; Qian Wang; Yan Zhang; Junfeng Du
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-08-31       Impact factor: 3.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.